The next wave of cosmetic innovation will not come from searching for another promising molecule hidden somewhere in nature. It will come from designing proteins and peptides with specific functions, then manufacturing them efficiently at industrial scale.
That represents a fundamental shift for the cosmetics industry.
For decades, ingredient innovation has been constrained by two approaches. Either identify something nature already makes and find a way to extract it. Or develop a synthetic alternative through chemistry.
Both have produced remarkable products, but both operate within clear boundaries.
Nature offers an extraordinary diversity of biomolecules, but only a tiny fraction can be sourced economically and sustainably. Chemistry enables countless innovations, yet some of biology’s complexity remains difficult or impossible to replicate.
Proteins illustrate this challenge particularly well.
Collagen has become one of the best-known cosmetic ingredients, but the collagen used in most products today isn’t human: it’s animal collagen, typically bovine, porcine, or marine sources. Species differences aren’t cosmetic details here. They affect how the human skin responds to it, and animal sourcing brings its own supply and safety questions. Recombinant, human-identical collagen changes that equation. It’s not a substitute for animal collagen, it’s the same molecule the body already makes, manufactured differently.
The more interesting shift may be happening elsewhere. A growing category of ingredients doesn’t try to replace collagen at all. Signal peptides like Matrixyl don’t add collagen to the skin, they instruct the skin’s own fibroblasts to produce more of it. These are entirely engineered molecules, often unrelated in structure to any natural human protein, designed purely for the signal they send. It’s a preview of where de novo protein design is headed: not better versions of what nature makes, but new molecules built around a single desired function.
The industry has spent years asking how existing ingredients could be sourced more sustainably, produced more efficiently, or replaced with alternatives. That remains an important challenge. But a far more interesting question is beginning to emerge: what if the ideal cosmetic ingredient doesn’t already exist?
Biology is becoming a design space
Recent advances in computational biology and artificial intelligence are changing how scientists think about proteins.
Instead of searching nature for molecules with useful properties, researchers can increasingly design proteins and peptides with desired characteristics from the ground up. Functional protein design is advancing rapidly. Protein binders can be engineered for specific molecular targets. Stability can be optimized computationally. Bioactive peptides can be designed with functions that would have been extraordinarily difficult to discover through traditional screening alone.
Perhaps most exciting is the emergence of de novo protein design. Rather than modifying proteins that already exist in nature, scientists can create entirely new protein sequences designed for a particular purpose.
For cosmetics, the possibilities are extensive.
Imagine proteins designed to interact with specific skin targets. Bioactive peptides engineered for greater stability in formulation. Novel antimicrobial peptides. Functional proteins optimized for texture, delivery, or performance. Entirely new classes of ingredients created around a cosmetic function rather than copied from nature.
The design space becomes dramatically larger than nature alone. But designing a protein is only part of the equation.
From digital protein to commercial ingredient
A protein sequence generated by AI is still only a digital design. Turning that sequence into a commercial ingredient requires solving an entirely different set of challenges.
- Can the protein actually be expressed inside a microbial production host?
- Will it fold correctly into its intended structure?
- Can high enough yields be achieved to make manufacturing economically viable?
- Can downstream processing purify it efficiently?
- Will the production process meet the quality, consistency, and cost requirements expected by the cosmetics industry?
These questions often determine whether a promising concept becomes a commercial product or remains an interesting publication. The manufacturability gap is increasingly becoming one of the defining challenges for next-generation protein innovation. As AI accelerates the ability to design proteins, industrial manufacturing becomes the critical enabling capability. This is where 21st.BIO plays a unique role.
21st.BIO bridges design and reality
Rather than competing with computational protein design, precision fermentation enables it. AI can help determine what should be built. Biomanufacturing determines whether it can be produced reliably, consistently, and at industrial scale.
Developing a manufacturing process is far more than inserting a DNA sequence into a microorganism. It requires selecting the right production host, engineering strains for high performance, optimizing fermentation conditions, designing efficient downstream purification, and creating a scalable process capable of delivering commercial quantities with consistent quality.
Every one of those steps influences the final economics of an ingredient.
The most elegant protein design has little value if manufacturing costs make it commercially impossible. Conversely, a manufacturable protein with robust industrial performance creates opportunities that extend well beyond the laboratory.
Manufacturing biology is no longer simply about reproducing proteins found in nature. It is becoming the platform that enables entirely new categories of ingredients.
A different question for the cosmetics industry
Biomanufacturing changes how cosmetic companies can think about innovation.
For many years, the discussion around precision fermentation has focused on replacing existing ingredients. That remains valuable. Familiar proteins such as collagen, elastin, keratin, or silk proteins can all benefit from scalable, animal-free production through precision fermentation.
Ingredients no longer need to be limited by what evolution happened to produce. They can be designed around functionality, performance, stability, manufacturability, or entirely new biological mechanisms.
Discovery becomes design.
From protein design to commercial reality
The convergence of AI and precision fermentation has the potential to reshape how cosmetic ingredients are developed.
AI expands what can be imagined. Precision fermentation expands what can be manufactured. Together, they create a pathway from computational design to commercial production.
At 21st.BIO, that is where the focus lies. The company develops and licenses precision fermentation technology that enables partners to manufacture proteins and peptides at industrial scale. Whether those molecules already exist in nature or have been designed from scratch, commercial success depends on building a manufacturing process that delivers quality, scalability, and cost competitiveness.
The next generation of cosmetic ingredients will likely include proteins that have never existed before. Their value will not come from where they were discovered, but from what they were designed to do.
The companies that succeed will be those able to combine computational innovation with industrial biotechnology.
Designing the protein is the beginning. Manufacturing it is what brings it to life.
Why Partner with 21st.BIO?
We don’t sell ingredients – we empower ingredient producers and brands with the tech and know-how to make them. By licensing our technology platform, partners gain:
- Proprietary strain engineering for protein production building on the legacy of the Novo Group
- A future-proof, animal-free protein that meets today’s market needs
- Faster time to market – expert technology enables faster regulatory approvals
- Expert guidance to identify high-impact applications and scale efficiently
Let’s build the future of cosmetics – sustainably, scientifically, and at scale.
